Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 1Neoplasms 1Nausea 1Breast Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
alizapride × Clear all
NCT01298193 2023-03-07

Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

Spanish Breast Cancer Research Group

Phase 4 Completed
212 enrolled 19 charts
Breast

Breast Neoplasms

NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed
494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡